Recent developments highlight GT Biopharma’s clinical and regulatory progress, management changes, and financial activities.

• GT Biopharma announced FDA clearance of the IND application for GTB-5550 TriKE®, targeting B7-H3 solid tumors, enabling clinical trial initiation [N1].
• The company submitted the IND application for GTB-5550 in January 2026, targeting solid tumors expressing B7-H3 [N2][N3].
• GT Biopharma advanced to Cohort 2 in the Phase 1 trial of GTB-3650 following a successful safety review of Cohort 1, progressing clinical development in hematologic malignancies [N5].
• David C. Mun-Gavin was appointed to the Board of Directors in June 2025, indicating management strengthening [N4].
• GT Biopharma withdrew its S-1 filing with the SEC in February 2025, halting plans for an upcoming securities offering [N8].
• The company announced a CFO transition and new financial leadership in June 2024, reflecting changes in financial management [N7].

GT Biopharma’s advancement of its second-generation TriKE® candidates, including GTB-3650 in Phase 1 trials and FDA clearance of GTB-5550 IND for solid tumors, demonstrates progress in clinical development. The use of camelid nanobody technology may enhance therapeutic potency and safety. The company’s exclusive platform rights and collaborations with leading NK cell experts support its innovation pipeline. Cost reductions and maintained liquidity provide operational stability. If clinical data supports efficacy and safety, the platform’s scalability and potential to treat multiple cancer types and autoimmune disorders could broaden its market opportunities.

GT Biopharma remains a clinical stage company with no approved products, facing inherent risks of clinical trial outcomes, regulatory approvals, and commercialization challenges. The company reported significant net losses and relies on external financing to fund operations, with liquidity limited to $6.8 million as of year-end 2025. Nasdaq listing compliance issues due to low stock price may impact investor perception. The withdrawal of a planned securities offering and financial restatements highlight operational and financial risks. Competition in immuno-oncology is intense, and the company’s novel platform must demonstrate clear clinical and commercial advantages to succeed.

GT Biopharma’s moat is based on its proprietary TriKE® and Dual Targeting TriKE® platforms that leverage natural killer cell biology to create targeted immuno-oncology therapies. The exclusive rights to these platforms, combined with the use of camelid nanobody technology for enhanced potency, provide a differentiated approach in the immunotherapy space. Collaborations with recognized experts in NK cell and IL-15 biology further strengthen its scientific foundation. The platform’s design to target multiple tumor antigens without patient-specific customization and its potential safety advantages over T-cell therapies contribute to its competitive positioning. However, as a clinical stage company, the moat is contingent on successful clinical development and regulatory approvals.

• Clinical Development Risk: GT Biopharma’s product candidates are in early clinical stages, and there is uncertainty regarding safety, efficacy, and regulatory approval outcomes.
• Financial Risk: The company has reported significant net losses and depends on external financing; limited cash reserves may constrain operations.
• Regulatory and Compliance Risk: The company faces regulatory scrutiny including Nasdaq listing compliance due to stock price and has had to restate financials, which may affect operations and investor confidence.
• Competitive Risk: The immuno-oncology field is highly competitive with multiple established and emerging therapies; differentiation and market acceptance are uncertain.

• GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing novel immuno-oncology products based on proprietary Tri-specific Killer Engager (TriKE®) and Tetra-specific Killer Engager (Dual Targeting TriKE®) fusion protein immune cell engager technology platforms that harness and enhance natural killer (NK) cells to target cancer cells or virus-infected cells [S1].
• The TriKE® and Dual Targeting TriKE® platforms generate therapeutics designed to activate NK cells to target specific proteins on cancer cells, including hematologic malignancies and solid tumors, without requiring patient-specific customization [S1].
• The company believes its TriKE® platform may be safer than T-cell immunotherapy due to less cytokine release syndrome and fewer neurological complications [S1].
• GT Biopharma's product pipeline includes GTB-3550 (first-generation TriKE® targeting CD33 in AML and MDS, development suspended), GTB-3650 (second-generation camelid nanobody TriKE® targeting CD33 for AML and MDS, in Phase 1 clinical trials), GTB-5550 (B7-H3 targeted TriKE® for solid tumors, IND cleared by FDA in February 2026), and GTB-7550 (TriKE® in development for lupus and autoimmune disorders) [S1].
• GTB-3650 uses camelid nanobody technology for enhanced potency and is in clinical development with enrollment started in January 2025 for relapsed/refractory AML and high-grade MDS [S1][N5].
• GTB-5550 targets B7-H3 expressed on a broad spectrum of solid tumors and received FDA IND clearance in February 2026, with manufacturing and clinical trial preparations ongoing [N1][S1].
• GT Biopharma has exclusive rights to the TriKE® platform and collaborates with key opinion leaders in NK cell biology, including Dr. Jeffrey Miller [S1][N7].
• The company reported a net loss of $28.35 million for the fiscal year ended December 31, 2025, with basic and diluted EPS of -6.68 USD per share [S1].
• As of December 31, 2025, GT Biopharma had cash and cash equivalents of approximately $6.8 million and a current ratio of 3.5, indicating liquidity to support ongoing operations [S1].
• Operating expenses decreased in the first half of 2025 compared to 2024, reflecting reduced research and development and selling, general and administrative costs [S1].
• GT Biopharma withdrew an S-1 filing with the SEC in February 2025, halting plans for an upcoming securities offering [N8].
• The company appointed David C. Mun-Gavin to its Board of Directors in June 2025 [N4].
• GT Biopharma's stock has traded below the Nasdaq minimum bid price requirement, resulting in a compliance period notification from Nasdaq in November 2025 [S1].
• The company has implemented a fully remote corporate structure as of July 2024 [S1].
• GT Biopharma's financial statements were restated in early 2026 to correct classification of certain stock purchase rights as liabilities, impacting reported net loss and equity [S1][S2].